Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CEACAM5 ADC SGN-CEACAM5C

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA; carcinoembryonic antigen-related cell adhesion molecule 5; CEACAM5; CD66e) and conjugated to a cytotoxic camptothecin-based payload, with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration of anti-CEACAM5 ADC SGN-CEACAM5C, the monoclonal antibody moiety targets and binds to CEA expressed on tumor cells. Upon binding and internalization, the payload is released. The camptothecin payload inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of CEA-expressing tumor cells. CEA, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its expression is limited in normal. healthy, adult tissues, but is overexpressed in various cancers.
Synonym:anti-CEA ADC SGN-CEACAM5C
anti-CEACAM5 antibody-drug conjugate SGN-CEACAM5C
antibody-drug conjugate SGN-CEACAM5C
Code name:SAR 445953
SAR-445953
SAR445953
SGN CEACAM5C
SGN-CEACAM5C
SGNCEACAM5C
Search NCI's Drug Dictionary